Shanghai Sigma-Audley New Material Technology: difference between revisions
Diff·revision 34 → 35·06:30, 5 May 2025
Difference between revision 34 and revision 35 of Shanghai Sigma-Audley New Material Technology. 3 lines changed; the page grew by 637 bytes.
| Revision 34 — 14:55, 28 Apr 2025 LotTraceLuka (talk) expand §Product range 7,531 bytes +27 | Revision 35 — 06:30, 5 May 2025 MolarMassMaeve (talk) rv restoration of unsourced claim 8,168 bytes +637 | ||
|---|---|---|---|
| 53 | Submitted reports on SSA material to July 2026 are concentrated on tirzepatide and semaglutide, with a smaller set on repair peptides. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and where a certificate accompanied the sample the two figures have generally been close.{{r|reports}} | 53 | Submitted reports on SSA material to July 2026 are concentrated on tirzepatide and semaglutide, with a smaller set on repair peptides. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and where a certificate accompanied the sample the two figures have generally been close.{{r|reports}} |
| 54 | 54 | ||
| + | 55 | The same limitation applies as everywhere in this sector: these are purchaser-submitted reports on purchaser-selected samples. They cannot be read as a sample of output, and the reported clustering may reflect which samples purchasers chose to have tested as much as anything about the material.{{r|reports}} None of the submitted certificates in this set reported a water content, so none of the purity figures can be converted into a mass.{{r|usp1503}} | |
| + | 56 | ||
| 55 | == References == | 57 | == References == |
| 56 | {{reflist}} | 58 | {{reflist}} |
| ⋮ | ⋮ | ||
| 59 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 61 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 60 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 62 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 63 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 61 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 64 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 62 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 65 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |